|
 ResearchEvidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapyMaría P Moreno1 1Laboratorio de Virología Molecular, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay 2Laboratoire Evolution Génomes et Spéciation (UPR9034), CNRS, 91198 Gif-sur-Yvette, France
Virology Journal 2006, 3:87doi:10.1186/1743-422X-3-87 The electronic version of this article is the complete one and can be found online at: http://www.virologyj.com/content/3/1/87
©
2006 Moreno et al; licensee BioMed Central Ltd. AbstractBackground/AimHepatitis C virus (HCV) has been the subject of intense research and clinical investigation as its major role in human disease has emerged. HCV circulates in vivo as a complex population of different but closely related viral variants, commonly referred to as a quasispecies. The extent to which recombination plays a role in the evolution of HCV quasispecies when patients are undergoing anti-viral therapy is currently unknown. In order to gain insight into these matters, we have performed a phylogenetic analysis of HCV quasispecies populations from six patients undergoing anti-viral therapy. MethodsPutative recombinant sequences were identified with the use of SimPlot program. Recombination events were confirmed by bootscaning, using putative recombinant sequence as a query. Statistical support for the presence of a recombination event was done by the use of LARD program. ResultsA crossing-over event in the NS5A gene in a HCV strain recovered after four weeks of treatment was identified in quasispecies from a patient with sustained response. Putative parental-like strains were identified as strains circulating in previous weeks on the same patient. ConclusionOnly one recombinant strain was detected in all patient quasispecies populations studied. The recombination break-point is situated on the PKR-binding region of NS5A. Although recombination may not appeared to be extensive in NS5A genes of HCV quasispecies populations of patients undergoing antiviral therapy, this possibility should be taken into account as a mechanism of genetic variation for HCV. BackgroundHepatitis C virus (HCV) is estimated to infect 170 million people worldwide and creates a huge disease burden from chronic, progressive liver disease [1] HCV has become a major cause of liver cancer and one of the commonest indications of liver transplantation [2,3]. HCV has been classified in the family Flaviviridae, although it differs from other members of the family in many details of its genome organization [1]. Like most RNA viruses, HCV circulates in vivo as a complex population of different but closely related viral variants, commonly referred to as a quasispecies [4-7]. HCV is an enveloped virus with an RNA genome of approximately 9400 bp in length [8,9]. Comparison of nucleotide sequences of variants recovered from different individuals and geographical regions has revealed the existence of at least six major genetic groups [1,10-12]. Each of the six major genetic groups of HCV contains a series of more closely related sub-types [1]. Interferon monotherapy provided the first hope for patients with chronic hepatitis C that the virus could be permanently eradicated. An important development in treating this disease was the recognition that the effects of interferon could be greatly enhanced by combining it with ribavirin, a nucleoside analogue. This combination regimen essentially doubled the sustained virological response rates seen with interferon alone. Recently, pegylated forms of interferon have been developed, and when that forms of interferon are used in combination with ribavirin, it demonstrates even better efficacy. For that reason, peginterferon alfa-2a and peginterferon alfa-2b are the latest innovations for the treatment of chronic hepatitis C [3,13,14]. Recombination plays a significant role in the evolution of RNA viruses by creating genetic variation. For example, the frequent recovery of poliovirus that results from recombination has the potential to produce "escape mutants" in nature as well as in experiments [15]. Recombination has also been detected in other RNA viruses for which multivalent vaccines are in use or in trials [16,17]. Recently, a natural intergenotypic recombinant (2 k/1b) of HCV has been identified in Saint Petersburg (Russia) [18,19]. Phylogenetic analyses of HCV strains circulating in Peru, demonstrated the existence of natural intra-genotypic HCV recombinant strains (1a/1b) circulating in the Peruvian population [20]. In these cases, the recombination events have taken place in the non-structural region of the HCV genome. Recombination break-points in HCV structural capsid genomic region has been recently identified [21]. Given the implications that recombination has for RNA virus evolution [16], it is clearly important to determine the extent to which recombination plays a role in the evolution of HCV quasispecies populations in vivo, when patients are undergoing anti-viral therapy. ResultsTo gain insight into possible recombination events, a phylogenetic profile analysis was carried out using HCV NS5A sequences from HCV quasispecies populations obtained by Puig-Basgoiti et al. [22] from patients undergoing anti-viral therapy. Sequences were obtained by the use of the LANL database [23] (for patients, strains accession numbers, quasispecies obtained at different time points during therapy and therapy outcome, see Table 1). Phylogenetic profile analysis was done by the use of the SimPlot program [24]. Interesting, when the analysis was carried out for strain AY378694 (obtained on week 4 in patient No. 7, see Table 1), a recombination point was detected at position 286 of the NS5A sequence alignment and two putative parental-like strains (AY378615 and AY378641, obtained on weeks 0 and 2 from the same patient, respectively) were identified (see Fig. 1 and Table 1). Table 1. Quasispecies population in HCV patients undergoing anti-viral therapya
In order to confirm these results, the same sequences were used for a bootscanning study [25]. The basic principle of bootscanning is that mosaicism is suggested when one observes high levels of phylogenetic relatedness between a query sequence and more than one reference sequence [25].When the putative recombinant strain identified in the previous analysis (AY378694) is used as a query, this is observed for this strain and the two putative parental-like strains previously detected (see Fig. 2). The same recombination break-point position is observed in the bootscanning analysis (see Figs. 1 and 2), confirming a recombination break-point at position 286 of the NS5A of strain AY378694.
To assess whether the recombination model we obtained gave a significantly better fit to the data than the null hypothesis of no recombination, we used LARD [26]. The results of these studies are shown in Fig. 3.
As it can be seen in the figure, simulations of sequence evolution under the null hypothesis (i.e., no recombination) gave strong statistical support for the alternative hypothesis of recombination (P < 0.004, Fig. 3). DiscussionThe extent to which recombination plays a role in the evolution of HCV quasispecies when patients are undergoing anti-viral therapy is currently unknown. In order to get insight into this issue, we performed phylogenetic studies on the NS5A gene of HCV quasispecies populations from patients undergoing antiviral therapy. We have selected NS5A since previous work by Enomoto et al. [27] suggested that the genetic heterogeneity of a specific domain of HCV NS5A, termed IFN sensitivity-determining region (ISDR), was related closely to response in Japanese patients. Although this issue continues to be controversial [22], analysis of the published information supports the hypothesis that a relationship exists between NS5A and response to therapy [28,29]. The results of these studies reveal that recombination can not be denied as an evolutionary mechanism for generating diversity in HCV in vivo, in patients undergoing anti-viral therapy (see Figs. 1 and 2). Recombination does not seems to play an extensive roll in the evolution of HCV quasispecies populations, at least by the study of NS5A genes, since only one recombinant isolate was observed among all HCV quasispecies populations studied. On the other hand, the true frequency of recombination may be underestimated, since a statistical significant number of differences among recombinant and putative parental-like strains are needed in order to achieve detection by current methods applied to detect recombination events. Recombination may serve two opposite purposes: exploration of a new combination of genomic region from different origins or rescuing of viable genomes from debilitated parental genomes [30]. Interestingly, the recombination break-point identified in recombinant strain AY378694 is situated on the PKR-binding region of NS5A ISDR [27,31] (see Fig. 4). Recent evidence suggests that HCV NS5A protein can repress PKR function in vivo, possibly allowing HCV to escape the antiviral effects of interferon [1,3,32,33]. An analysis of NS5A translated sequences of recombinant and putative parental-like virus suggests the possibility that recombinant isolate AY378694 may have acquired amino acids known to be present in HCV strains resistant to interferon treatment (see Fig. 4), although more work is needed in order to test this hypothesis, since the results found for the ISDR still remains a controversial issue [22]. For that reason, although recombination may not appeared to be extensive in NS5A genes of HCV quasispecies populations of patients undergoing antiviral therapy, this possibility should be taken into account as a mechanism of genetic variation for HCV.
ConclusionOnly one recombinant strain was detected in all patient quasispecies populations studied. The recombination break-point identified in strain AY378694 is situated on the PKR-binding region of NS5A. The results of these studies reveal that recombination events can be observed in patients undergoing anti-viral therapy. Recombination can not be denied as a mechanism of genetic variation for HCV. MethodsPatients and strainsPatients and strains refereed in these studies belong to a recent study done by Puig-Basagoiti et al. [22]. All patients had genotype 1b infection. Treatment consisted of the administration of IFN-α-2b and ribavirin (see ref. [22]). SequencesNS5A sequences from the study done by Puig-Basagoity et al. [22] were obtained from the HCV LANL database [23] (for patient identification, quasispecies accession numbers obtained at each week of therapy and therapy outcome, see Table 1). Sequences were aligned using the CLUSTAL W program [34]. Recombination analysisPutative recombinant sequences were identified with the SimPlot program [24]. This program is based on a sliding window method and constitutes a way of graphically displaying the coherence of the sequence relationship over the entire length of a set of aligned homologous sequences. The window width and the step size were set to 200 bp and 20 bp, respectively. Bootscanning analysisThe results obtained in the recombination analysis were confirmed using a bootscanning analysis [25]. The window width and the step size were set to 200 bp and 20 pb, respectively. LARD analysisTo assess whether the recombination model we obtained gave a significantly better fit to the data than the null hypothesis of no recombination, we used LARD [26]. Briefly, for every possible breakpoint, the sequence alignment was divided into two independent regions for which the branch lengths of a tree of the putative recombinant and its two parent sequences were optimised. The two results (likelihoods) obtained by using the separate regions were then combined to give a likelihood score for that breakpoint position and the breakpoint position that yielded the highest likelihood then was compared, by using a likelihood ratio test, to the likelihood obtained from the same data under a model that permitted no recombination. The likelihood ratio obtained by using the real data were evaluated for significance against a null distribution of likelihood ratios produced by using Monte Carlo simulation of sequences generated without recombination. Sequences were simulated 1,000 times by using the maximum likelihood model parameters and sequence lengths from the real data using Seq-Gen [35]. Competing interestsThe author(s) declare that they have no competing interests. Authors' contributionsJC and PM conceived the study. JC, PM and LL designed the analysis. JC and PM performed the SimPlot and Bootscanning analysis. DC performed the LARD analysis and contributed to the discussion of all results found in this work. JC wrote the paper. AcknowledgementsThis work was supported by ICGEB, PAHO, and RELAB through Project CRP.LA/URU03-032. International Atomic Energy Agency through project ARCAL 6050 and from DINACYT (Uruguay) through Project Fondo Clemente Estable 05/039 and Project No. 8006. References
Have something to say? Post a comment on this article! |
|
|
|
 |   | Log on / register BioMed Central home | Journals A-Z | Feedback | Support | My details |
on Google Scholar
author email
corresponding author email
Figure 1.
Figure 2.
Figure 3.
Figure 4.|
|
| © 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. |